Online Only Articles

GFI1 is required for RUNX1/ETO positive acute myeloid leukemia

Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands
Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany
Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany;Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University Duisburg-Essen, Germany
Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands
Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany
Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany
Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany
Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands
Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands
Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, The Netherlands
Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, The Netherlands
Department of Hematology, University Medical Center Groningen, University of Groningen, The Netherlands
Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands
Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany
Department of Medicine II-Hematology/Oncology, Goethe University, Frankfurt/Main, Germany
Institut de recherches cliniques de Montréal (IRCM), Hematopoiesis and Cancer Research Unit, and Université de Montréal, Canada
Department of Transfusion Medicine, Cell Therapeutics and Hemostaseology, Ludwig-Maximilian University Hospital, Munich, Germany
Department of Pathology & Division of Biological Sciences, University of California San Diego, La Jolla, USA
Department of Pathology & Division of Biological Sciences, University of California San Diego, La Jolla, USA
Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands
Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany;Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Germany
Vol. 103 No. 9 (2018): September, 2018 https://doi.org/10.3324/haematol.2017.180844